1832 Asset Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$92.9M Sell
100,966
-387,847
-79% -$393M 0.09% 168
2025
Q4
$525M Buy
488,813
+386,975
+380% +$370M 0.4% 39
2025
Q3
$77.7M Buy
101,838
+58,010
+132% +$43.2M 0.06% 157
2025
Q2
$34.2M Sell
43,828
-224,972
-84% -$175M 0.03% 233
2025
Q1
$222M Buy
268,800
+38,930
+17% +$32.4M 0.2% 70
2024
Q4
$177M Sell
229,870
-165,796
-42% -$137M 0.15% 86
2024
Q3
$351M Sell
395,666
-246,765
-38% -$222M 0.27% 41
2024
Q2
$582M Buy
642,431
+116,956
+22% +$93.6M 0.47% 22
2024
Q1
$409M Buy
525,475
+187,563
+56% +$133M 0.24% 34
2023
Q4
$197M Sell
337,912
-451,130
-57% -$263M 0.28% 75
2023
Q3
$424M Buy
789,042
+17,486
+2% +$9.01M 0.6% 35
2023
Q2
$362M Buy
771,556
+625,048
+427% +$262M 0.43% 43
2023
Q1
$50.3M Sell
146,508
-887,220
-86% -$299M 0.07% 178
2022
Q4
$378M Buy
1,033,728
+25,807
+3% +$9.15M 0.63% 36
2022
Q3
$326M Sell
1,007,921
-479,682
-32% -$152M 0.61% 40
2022
Q2
$482M Sell
1,487,603
-134,093
-8% -$40.3M 0.85% 30
2022
Q1
$458M Buy
1,621,696
+1,569,368
+2,999% +$404M 0.65% 41
2021
Q4
$14.4M Sell
52,328
-939,391
-95% -$238M 0.03% 272
2021
Q3
$228M Buy
991,719
+352,034
+55% +$86.9M 0.43% 66
2021
Q2
$145M Buy
639,685
+439,185
+219% +$88.2M 0.28% 99
2021
Q1
$37M Buy
200,500
+98,520
+97% +$19.3M 0.08% 195
2020
Q4
$17.1M Buy
101,980
+101,914
+154,415% +$15.2M 0.04% 248
2020
Q3
$10K Sell
66
-964,400
-100% -$149M ﹤0.01% 645
2020
Q2
$158M Sell
964,466
-359,720
-27% -$55.2M 0.47% 63
2020
Q1
$185M Buy
1,324,186
+1,321,470
+48,655% +$182M 0.67% 45
2019
Q4
$304K Sell
2,716
-31,956
-92% -$3.7M ﹤0.01% 502
2019
Q3
$3.85M Buy
34,672
+34,606
+52,433% +$3.85M 0.01% 323
2019
Q2
$7K Sell
66
-1,497,347
-100% -$176M ﹤0.01% 642
2019
Q1
$194M Sell
1,497,413
-214,433
-13% -$26.1M 0.66% 43
2018
Q4
$198M Buy
1,711,846
+1,551,150
+965% +$173M 0.78% 37
2018
Q3
$17.3M Buy
160,696
+159,530
+13,682% +$15.9M 0.06% 192
2018
Q2
$105K Sell
1,166
-202,025
-99% -$16.6M ﹤0.01% 483
2018
Q1
$15.5M Buy
203,191
+202,091
+18,372% +$16.3M 0.06% 200
2017
Q4
$93K Sell
1,100
-5,642
-84% -$480K ﹤0.01% 509
2017
Q3
$562K Buy
6,742
+5,642
+513% +$463K ﹤0.01% 461
2017
Q2
$91K Sell
1,100
-2,984
-73% -$243K ﹤0.01% 521
2017
Q1
$344K Sell
4,084
-1,288,937
-100% -$103M ﹤0.01% 506
2016
Q4
$30.8M Buy
1,293,021
+1,175,921
+1,004% +$87.6M 0.05% 253
2016
Q3
$9.4M Buy
117,100
+115,971
+10,272% +$9.28M 0.04% 271
2016
Q2
$89K Buy
1,129
+29
+3% +$2.18K ﹤0.01% 491
2016
Q1
$79K Hold
1,100
﹤0.01% 476
2015
Q4
$93K Hold
1,100
﹤0.01% 490
2015
Q3
$92K Hold
1,100
﹤0.01% 480
2015
Q2
$92K Sell
1,100
-20
-2% -$1.52K ﹤0.01% 514
2015
Q1
$81K Sell
1,120
-180
-14% -$12.8K ﹤0.01% 478
2014
Q4
$90K Buy
1,300
+200
+18% +$13.5K ﹤0.01% 490
2014
Q3
$71K Hold
1,100
﹤0.01% 496
2014
Q2
$68K Hold
1,100
﹤0.01% 493
2014
Q1
$65K Buy
+1,100
New +$61.4K ﹤0.01% 504

Other funds holding LLY

1832 Asset Management's LLY Position: Q1 2026 in Review

1832 Asset Management reduced its Eli Lilly (LLY) stake by 79% in Q1 2026, selling an estimated $393M and leaving 100,966 shares worth $92.9M. The position accounts for 0.09% of the portfolio, ranked #168.

1832 Asset Management first reported a position in LLY in Q1 2014 and has held it in 49 quarters since. The position peaked at $582M in Q2 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • 1832 Asset Management held 100,966 shares of Eli Lilly worth $92.9M as of Q1 2026.
  • 1832 Asset Management sold 387,847 Eli Lilly shares in Q1 2026, an estimated $393M.
  • Eli Lilly made up 0.09% of 1832 Asset Management's portfolio in Q1 2026, its #168 holding.
  • 1832 Asset Management first reported a position in Eli Lilly in Q1 2014 and has held it in 49 quarters since.
  • 1832 Asset Management's Eli Lilly position peaked at $582M in Q2 2024.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on 1832 Asset Management's 13F filing for Q1 2026, filed 14 May 2026.